

Bod signs agreement with Symbion, national wholesaler of healthcare services and products

- **Symbion is a leading Australian pharmacy wholesaler servicing over 3,500 customers across Australia – including Good Price, Terry White Chemmart and Blooms**
- **Products now live - entire natural medicines range as well as leading pregnancy supplement, Mamacare made available through Symbion at the end of May**
- **Follows Bod’s agreement with API giving the Company access to over two thirds of the pharmacy market - agreements with two of Australia’s leading pharmacy wholesalers now secured**
- **Agreement allows for Bod to build greater market positioning, improved working capital management and centralised deliveries**
- **Incoming Executive Chairman George Livery (formerly Swisse Wellness) expects further distribution deals to be expedited in the lead up to the new financial year**

Sydney, Australia – 5 June 2018: Developer and distributor of natural, evidence-based cosmetics, natural medicines and health products, Bod Australia Limited (“Bod” or the “Company”) (ASX: BDA) is pleased to advise that it has secured an agreement with one of Australia’s leading pharmaceutical wholesalers, Symbion. Under the agreement, Symbion will now stock Bod’s range of natural medicines, as well as pregnancy supplement, Mamacare.

Symbion is one of Australia’s largest pharmacy wholesalers, owned by the listed company EBOS Group Ltd, it provides products and services to over 3,500 pharmacy customers across the nation. The business has 10 warehouses located across the country and coordinates daily deliveries to pharmacies through longstanding relationships with delivery partners.

Similar to the Company’s agreement with API (refer ASX announcement: 5 April 2018), this allows Bod to better utilise working capital by leveraging centralised delivery points and more stringent payment periods. It also allows Symbion’s 3,500 strong retailer customer base simplified and convenient access to the Company’s products ensuring Bod’s products achieve greater market shares across pharmacies and specialty retailers.

Board and Management are pleased to advise that all ranges and associated stock keeping units (SKU’s) are now live in Symbion’s system. The Company has also begun working in conjunction with the wholesaler to ensure its products are promoted adamantly.

Bod Australia CEO Jo Patterson said: “We are excited to have our natural medicines range and Mamacare pregnancy supplement stocked with another one of Australia’s leading pharmacy wholesalers.

“Not only does this agreement provide ongoing validation of our product range, but coupled with the recent progression of our relationship with API, it provides the Company with access to over two thirds of the Australian pharmaceutical market.

“We look forward to working with Symbion to promote our products through their network of over 3,500 pharmacies and specialty retailers to ensure Bod’s products achieve greater market penetration and drive revenue growth.

Incoming Executive Chairman George Livery added: “This is a significant achievement for the Company and provides another strong foundation for revenue and sales growth.

“We are continuing to pursue additional opportunities to increase our distribution footprint and expect to update shareholders in the near term as these developments materialise.”

For more information: bodaustralia.com

- ENDS -

About Bod Australia

Bod Australia Limited operates two integrated business units. The Company is a developer and distributor of cosmetics, natural medicines and health supplements, focused on all natural, evidence based products. Bod has developed a significant distribution footprint in the Australian market with access to over 900 pharmacies and is also targeting Asian markets through key daigou relationships. Bod Australia has also build a multi-faceted cannabis business underpinned by a supply and collaboration agreement with Swiss botanical extracts manufacturer, Linnea Natural Pharma Solutions and an exclusive licence and manufacturing agreement with Singapore listed company iX Biopharma. The Company aims to develop a range of over the counter and therapeutic products based on GMP-certified cannabis extracts.

For more information please contact:

Jo Patterson
Bod Australia
+61 2 9199 5018

Henry Jordan – Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 431 271 538